Through rational molecular modifications based on an understanding of the structure of logical alternative tyrosine kinase targets, improved activity against the
platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR)
